Ascrinvacumab
Modify Date: 2025-08-25 13:32:33
Ascrinvacumab structure
|
Common Name | Ascrinvacumab | ||
|---|---|---|---|---|
| CAS Number | 1463459-96-2 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of AscrinvacumabAscrinvacumab (PF-03446962) is a human IgG2 monoclonal antibody targets ALK-1. Ascrinvacumab shows binding efficiency with human ALK1 with a Kd value of 7 nM. Ascrinvacumab can be used for the research of hepatocellular carcinoma (HCC)[1]. |
| Name | Ascrinvacumab |
|---|
| Description | Ascrinvacumab (PF-03446962) is a human IgG2 monoclonal antibody targets ALK-1. Ascrinvacumab shows binding efficiency with human ALK1 with a Kd value of 7 nM. Ascrinvacumab can be used for the research of hepatocellular carcinoma (HCC)[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Ascrinvacumab 与细胞人 ALK1 结合，Kd 值为 7 nm[1]。 Ascrinvacumab (30 分钟) 阻断 BMP9 和 FCS 诱导的应答，缓解 BMP9 诱导的 Smad1 磷酸化强度和持续时间[1]。 Ascrinvacumab (0.01-10 μg/mL; 2 h) 抑制 BMP9 结合到 ALK1[1]。 Ascrinvacumab (40 μg/mL; 2 h) 有效抑制人脐静脉内皮细胞 (HUVECs) 的内皮萌发[1]。 |
| In Vivo | Ascrinvacumab 联合贝伐单抗 (bevacizumab; anti-VEGF) 可降低人血管密度，提高抗肿瘤疗效在小鼠嵌合体肿瘤模型中[1]。 |
| References |
| No Any Chemical & Physical Properties |